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Metabolic Syndrome Modulates 
Association between Endothelial 
Lipase and Lipid/Lipoprotein 
Plasma Levels in Acute Heart 
Failure Patients
Ines Potočnjak1, Matias Trbušić1,2, Sanda Dokoza Terešak1, Bojana Radulović3, Gudrun 
Pregartner4, Andrea Berghold4, Beate Tiran5, Gunther Marsche6, Vesna Degoricija1,2 & Saša 
Frank7
We hypothesised that the established association of endothelial lipase (EL) plasma levels with 
atherogenic lipid profile is altered in acute heart failure (AHF) and additionally affected by overlapping 
metabolic syndrome (MetS). We examined the association of EL plasma levels and lipid/lipoprotein 
plasma levels in AHF patients without and with overlapping MetS. The study was performed as a single-
centre, observational study on 152 AHF patients, out of which 85 had overlapping MetS. In the no-MetS 
group, EL plasma levels were significantly positively correlated with plasma levels of atherogenic 
lipids/lipoproteins, including total cholesterol, low-density lipoprotein (LDL)-cholesterol, total LDL 
particles and triglycerides, but also with plasma levels of antiatherogenic high-density lipoprotein 
(HDL)-cholesterol, total HDL particles and small HDL particles. In the MetS group, EL plasma levels 
were positively correlated with triglyceride and small LDL-particle levels, and significantly negatively 
correlated with plasma levels of large HDL particles as well as with LDL- and HDL-particle size, 
respectively. EL- and lipid/lipoprotein- plasma levels were different in the no-MetS patients, compared 
to MetS patients. The association of EL with atherogenic lipid profile is altered in AHF and additionally 
modified by MetS, which strongly modulates EL- and lipid/lipoprotein-plasma levels in AHF.
Endothelial lipase (EL) is a member of the triglyceride lipase gene family, expressed primarily by vascular 
endothelial cells (ECs) and to a lesser extent smooth muscle cells (SMCs) and macrophages1, 2. EL is a phospholi-
pase which has a high affinity for high-density lipoprotein-phospholipids. EL expression can be induced by tumor 
necrosis factor-α, interleukin-1β and biomechanical forces in vascular EC3, 4, by angiotensin II and hypertension 
in vascular SMCs5 as well as by lipopolysaccharide in macrophages6. EL concentrations in human plasma have 
been found to be strongly associated with inflammatory markers, such as C-reactive protein (CRP), interleukin-6 
(IL-6) and secretory phospholipase A2 type IIA levels7. EL plasma levels are increased in metabolic syndrome 
(MetS) and associated with subclinical atherosclerosis, measured as coronary artery calcification8. In contrast to 
EL plasma levels, the EL activity in post-heparin plasma was not significantly increased in humans with MetS, but 
was dependent on the degree of insulin resistance9. EL is expressed in human and mouse atherosclerotic plaques 
mainly by macrophages and to a lesser extent by SMCs10–12. EL modulates HDL plasma levels and functional-
ity13–16, and its plasma levels are associated with a proatherogenic lipid profile8, 17. Moreover, EL was recognized as 
an important provider of lipoprotein-derived fatty acids to cardiac tissue of mice with pressure overload-induced 
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heart failure (HF), a pathophysiological condition accompanied by an increased energy demand and a decreased 
cardiac lipoprotein lipase (LPL) expression; EL deficient mice presented more severe HF than wild type mice due 
to decreased cardiac uptake of fatty acids18.
Decreased lipid synthesis and decreased intestinal lipid absorption due to venous congestion, a consequence 
of right-sided heart failure, underlie the low lipid plasma levels and deranged lipid metabolism in HF19, 20. 
Considering the disturbed lipid metabolism in HF and metabolic perturbations with upregulation of EL in MetS8, 
21,we hypothesised that the established association of EL plasma levels and atherogenic lipid profile, including 
increased triglycerides, total cholesterol and apoB-containing lipoproteins, as well as decreased HDL-cholesterol 
plasma levels8, 15–17, is altered in acute HF (AHF) and additionally affected by overlapping MetS.
Results
Patients’ clinical characteristics. Of the152 AHF patients included in the study, 85 (55.9%) had MetS 
(Table 1). The MetS and the no-MetS groups did not differ significantly regarding gender, age, mean arterial pres-
sure (MAP), New York Heart Association (NYHA) classification, time of AHF onset, EF, smoking and final clini-
cal presentation (Table 1). As obvious from patients’ age none of the groups contained premenopausal women. In 
line with the MetS definition, the MetS group had significantly higher body weight, body mass index (BMI) and 
waist circumference, as well as a higher incidence of hypertension, type 2 diabetes mellitus (T2DM), hyperlipi-
daemia/hypertriglyceridaemia and hypercholesterolaemia (Table 1). Additionally, the MetS group had a higher 
incidence of chronic obstructive pulmonary disease (COPD) (Table 1). The no-MetS and MetS groups had a 
similar incidence of enlarged liver, ascites and peripheral oedema, the signs implying venous overload due to 
right-sided heart failure (Table 1).
Laboratory parameters. In accordance with previous reports8, 17, EL plasma levels were higher in 
the MetS group compared with the no-MetS group (Table 2). Total cholesterol and low-density lipoprotein 
(LDL)-cholesterol were similar in the MetS and the no-MetS groups (Table 2). In line with the MetS definition, 
the triglyceride plasma levels were significantly higher, and HDL-cholesterol plasma levels were significantly 
lower in the MetS compared to the no-MetS group (Table 2). Additionally, we found significantly higher plasma 
levels of large very low-density lipoprotein particles (LVLDL-p) and significantly lower plasma levels of large 
HDL particles (LHDL-p) in the MetS compared with the no-MetS group (Table 2). Furthermore, the size of HDL 
particles (HDL-s) was significantly smaller in the MetS compared with the no-MetS group (Table 2). The concen-
trations of CRP and interleukin-6 (IL-6) were similar in both groups (Table 2).
Correlation of EL plasma levels and plasma lipids/lipoproteins. In the no-MetS group, EL plasma 
levels were significantly positively correlated with total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyc-
erides, total low-density lipoprotein particle concentrations (TLDL-p), total (T) HDL-p and small (S) HDL-p 
(Table 3). In the MetS group, similarly to the no-MetS group, EL plasma levels were positively correlated with tri-
glyceride levels (Table 3). In contrast to the no-MetS group, in the MetS group EL was significantly positively cor-
related with small (S)LDL-particles and significantly negatively correlated with plasma levels of LHDL-particles 
as well as with LDL-s and HDL-s (Table 3). As shown by partial correlation analysis, T2DM did not affect the 
correlation between EL and lipids/lipoproteins (Supplementary Table S1).
Impact of venous overload on EL and lipid/lipoprotein plasma levels. Considering the role of 
venous congestion in the deranged lipid metabolism in HF, together with the increased EL and metabolic pertur-
bations in MetS, we examined whether venous volume overload affects EL- and lipid/lipoprotein- plasma levels, 
and whether the impact of venous volume overload is modulated by MetS. For this purpose we compared EL- and 
lipid/lipoprotein- plasma levels in the no-MetS and the MetS patients, having none vs. any one or more of the 
three signs implying volume overload (enlarged liver, peripheral oedema or ascites), as a consequence of right- 
sided HF. Within the no-MetS group, plasma levels of EL, total cholesterol, LDL-cholesterol, HDL-cholesterol 
and LLDL-p were significantly decreased in patients with sign(s) implying volume overload (Table 4). This was 
not observed in the MetS group (Table 4). Triglyceride-, THDL-p- and SHDL-p- plasma levels were significantly 
decreased in both the no-MetS and MetS groups, and plasma levels of SLDL-p were decreased only in the MetS 
group with sign(s) implying volume overload, compared to patients with no sign(s) (Table 4).
Discussion
We hypothesised that the reported association of EL and increased plasma triglycerides, total cholesterol and 
apoB-containing lipoproteins, as well as with decreased HDL-cholesterol plasma levels8, 15–17, is altered in AHF 
and additionally affected by MetS. To test our hypothesis, we examined the association of EL plasma levels with 
plasma lipids/lipoproteins in AHF patients without and with overlapping MetS. To our knowledge, this is the first 
study on EL and its association with plasma lipids/lipoproteins in AHF.
Disturbed haemodynamics and related volume overload with concomitant venous congestion have been 
found to be associated with impaired renal function, impaired absorption of water, electrolytes, and glucose, 
as well as decreased plasma levels of lipids and lipoproteins in HF patients19, 22. Decreased lipid synthesis or 
decreased absorption, likely due to venous congestion may underlie the reportedly decreased lipid and lipopro-
tein levels in HF19.
We found a strong positive correlation between EL plasma levels and plasma levels of lipids and lipopro-
teins primarily in the no-MetS group (Table 3). Positive associations with total cholesterol, LDL-cholesterol 
and triglycerides are in accordance with previous findings8. However, a strong positive association of EL with 
HDL-cholesterol-, THDL-p- and SHDL-p- concentrations was in sharp contrast to previous studies reporting 
either no7, 23 or a negative association of EL with HDL-cholesterol- and HDL-p- plasma concentrations8, 15–17. A 
possible explanation for this finding might be that the observed relationship does not reflect the enzyme-substrate 
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interaction but rather a concomitant regulation of EL- and HDL- levels into the same direction by the underlying 
AHF pathophysiology. Indeed, the levels of EL, HDL-cholesterol, THDL-p and SHDL-p, but not LHDL-p, were 
decreased by venous volume overload in the no-MetS group, in which the levels of SHDL-p were slightly affected 
by HF severity (Supplementary Table S2). However, partial correlation analyses revealed only a weak overall 
impact of venous volume overload (Supplementary Table S3) and HF severity (Supplementary Table S4) on the 
correlation between EL- and lipid/lipoprotein plasma levels in the no-MetS group. Observed positive correlation 
between EL and SHDL-p plasma levels, but no correlation with LHDL-p levels and HDL-s in the no-MetS group 
Variable
no-MetS 
n = 67 
(44.1%)
MetS n = 85 
(55.9%) P-value
Baseline characteristics
 Female (n) 41 (61.2%) 38 (44.7%) 0.051
 Age (years) 76.6 (10.12) 74.1 (10.28) 0.137
 MAP (mmHg) 104.8 (22.64) 106.0 (21.44) 0.739
 Body weight (kg) 72.6 (16.5) 91.1 (18.1) <0.001
 BMI (kg/m2) 25.7 (4.03) 31.3 (5.10) <0.001
 Waist circumference 
(cm) 100.9 (15.13) 119.3 (15.21) <0.001
 Smoking 14 (20.9%) 24 (28.2%) 0.348
 NYHA Class 2 4 (6.0%) 7 (8.2%)
0.846 NYHA Class 3 38 (56.7%) 45 (52.9%)
 NYHA Class 4 25 (37.3%) 33 (38.8%)
Classifications
 De novo 18 (26.9%) 29 (34.1%)
0.380
 Worsening of CHF 49 (73.1%) 56 (65.9%)
 HFrEF 37 (58.7%) 46 (56.8%)
0.866
 HFpEF 26 (41.3%) 35 (43.2%)
Final Clinical Presentation
 Worsening of CHF 37 (55.2%) 41 (48.2%)
0.178
 Hypertensive AHF 11 (16.4%) 11 (12.9%)
 Isolated Right Side AHF 1 (1.5%) 6 (7.1%)
 ACS and HF 6 (9.0%) 17 (20.0%)
 Pulmonary edema 11 (16.4%) 9 (10.6%)
 CS 1 (1.5%) 1 (1.2%)
Comorbidities
 Atherosclerosis 28 (41.8%) 41 (48.2%) 0.512
 CM 47 (70.1%) 66 (77.6%) 0.351
 ACS 7 (10.4%) 17 (20.0%) 0.122
 Hypertension 55 (82.1%) 81 (95.3%) 0.014
 T2DM 17 (25.8%) 61 (71.8%) <0.001
 Hyperlipidaemia 19 (28.4%) 41 (48.2%) 0.019
 Hypercholesterolaemia 20 (29.9%) 39 (45.9%) 0.047
 COPD 12 (17.9%) 29 (34.1%) 0.028
 CKD 24 (35.8%) 26 (30.6%) 0.602
 Anemia 17 (25.4%) 22 (25.9%) 1.000
Signs at admission
 Enlarged liver 24 (35.8%) 29 (34.1%) 0.865
 Ascites 6 (9.0%) 15 (17.6%) 0.157
 Peripheral edema 45 (67.2%) 60 (70.6%) 0.725
 Any single sign or 
combination thereof 49 (73.1%) 61 (71.8%) 1.000
Table 1. Baseline characteristics, classification, comorbidities and signs at admission. Metric/continuous/
quantitative variables are presented as mean and standard deviation. For categorical/qualitative variables the 
absolute and relative frequencies are shown as n (%) and significant differences depicted in bold. ACS-Acute 
Coronary Syndrome; AHF-Acute Heart Failure; BMI-Body Mass Index; BW-Body Weight; CHF-Chronic 
Heart Failure; CKD-Chronic Kidney Disease, CM-Cardiomyopathy; COPD-Chronic Obstructive Pulmonary 
Disease; CS-Cardiogenic Shock; EF-Ejection Fraction; HFpEF-Heart Failure with preserved Ejection Fraction; 
MAP-Mean arterial pressure; HFrEF- Heart Failure with reduced Ejection Fraction; NYHA-New York Heart 
Association Functional Classification; T2DM-Type 2 Diabetes Mellitus.
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(Table 3) suggests a disruption of the established relationship between EL and HDL, whereby EL, by acting on 
HDL, converts LHDL-p into SHDL-p16, 24. This finding is in line with a recent report on metabolic studies in 
humans, suggesting that complex multiple-sized HDL-p are simultaneously secreted from liver cells, whereby 
Variable n no-MetS n MetS P-value
EL (pg/mL) 66 383.1 [74.1–1013.4] 82
462.3 [157.6–
1407.7] 0.013
IL-6 (pg/mL) 66 18.7 [0.4–300.0] 82 21.0 [1.2–300.0] 0.483
CRP (µg/mL) 66 9.0 [0.2–169.0] 85 10.6 [0.8–247.4] 0.347
Total cholesterol (mmol/L) 66 3.8 [2.2–9.1] 85 3.8 [1.7–7.7] 0.672
LDL-cholesterol (mmol/L) 67 2.3 [0.8–6.3] 85 2.3 [1.0–6.0] 0.281
HDL-cholesterol (mmol/L) 67 1.1 [0.5–2.3] 85 0.9 [0.3–3.6] 0.004
Triglycerides (mmol/L) 67 1.0 [0.5–3.0] 85 1.2 [0.6–4.3] 0.001
LVLDL-p (nmol/L) 29 1.9 [1.5–5.1] 47 2.7 [1.5–10.6] <0.001
TLDL-p (nmol/L) 60 1100.5 [564–2488] 75 1097 [360–2425] 0.856
LLDL-p (nmol/L) 59 684 [304–2078] 67 689 [300–1160] 0.839
SLDL-p (nmol/L) 58 451 [176–1440] 74 473.5 [172–1331] 0.150
THDL-p (nmol/L) 60 21924 [3711–37506] 75
20774 [7910–
36951] 0.713
LHDL-p (nmol/L) 53 6304 [2943–14726] 55
4761 [2829–
14921] <0.001
SHDL-p (nmol/L) 48 17261 [7086–32390] 67
16502 [6332–
34210] 0.858
VLDL-s (nm) 60 47.1 [39.4–52.3] 75 46.9 [37.1–51.3] 0.968
LDL-s (nm) 60 21.3 [20.7–22.7] 75 21.2 [20.2–21.9] 0.084
HDL-s (nm) 60 9.4 [8.5–10.5] 75 9.0 [8.3–10.6] <0.001
Table 2. Laboratory parameters. Results are presented as median, minimum and maximum. Significant 
differences between MetS and noMetS patients were calculated with Mann-Whitney U-test and are depicted 
in bold. HDL-high density lipoprotein; LDL-low-density lipoprotein; IL-6-interleukin 6; hsCRP-C-reactive 
protein; EL-endothelial lipase; LVLDL-p –large very low-density lipoprotein particles; TLDL-p –total LDL 
particles; LLDL-p –large LDL particles; SLDL-p –small LDL-p; THDL-p –total HDL-particles; LHDL-p –large 
HDL-p; SHDL-p –small HDL-p; VLDL-s –VLDL size; LDL-s –LDL size; HDL-s –HDL size; n- number of 
samples in which particular parameter was analysed. Reference values: Triglycerides (mmol/L) 0.5–1.8 (male); 
0.5–1.5 (female); total cholesterol (mmol/L) 3.5–5.2; HDL-cholesterol (mmol/L) ≥1.4 (male); ≥1.7 (female); 
LDL-cholesterol (mmol/L) 2.0–3.9. aSI measurements. To convert to mg/dL, multiply Triglycerides by 89 and 
total cholesterol, HDL-cholesterol or LDL-cholesterol by 39.
no-MetS MetS
rho p-value rho p-value
Total cholesterol (mmol/L) 0.46 <0.001 0.19 0.090
LDL-cholesterol (mmol/L) 0.38 0.002 0.16 0.153
HDL-cholesterol (mmol/L) 0.45 <0.001 −0.11 0.318
Triglycerides (mmol/L) 0.30 0.013 0.29 0.007
LVLDL-p (nmol/L) 0.21 0.272 0.12 0.430
TLDL-p (nmol/L) 0.28 0.029 0.16 0.161
LLDL-p (mmol/L) 0.24 0.071 −0.02 0.857
SLDL-p (nmol/L) 0.06 0.650 0.24 0.042
THDL-p (nmol/L) 0.47 <0.001 0.17 0.153
LHDL-p (nmol/L) 0.13 0.348 −0.38 0.004
SHDL-p (nmol/L) 0.34 0.019 0.22 0.076
VLDL-s (nm) 0.14 0.286 −0.12 0.304
LDL-s (nm) 0.10 0.457 −0.24 0.036
HDL-s (nm) −0.12 0.352 −0.32 0.006
Table 3. Spearman correlation of EL plasma levels with plasma lipids and lipoproteins. HDL-high density 
lipoprotein; LDL-low-density lipoprotein; LVLDL-p –large very low-density lipoprotein particle; TLDL-p –total 
LDL particles; LLDL-p –large LDL particles; SLDL-p –small LDL-p; THDL-p –total HDL-particles; LHDL-p 
–large HDL-p; SHDL-p –small HDL-p; VLDL-s –VLDL size; LDL-s –LDL size; HDL-s –HDL size. Significant 
associations are depicted in bold.
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extracellular HDL remodelling represents a minor contribution to HDL-class diversity25. Notably, the EL mass 
determined in the present study may not necessarily be related to EL activity, which has been shown in a recent 
study to be negatively correlated with HDL-cholesterol in both healthy and MetS subjects9. Furthermore, since EL 
presents mainly phospholipase activity, the association of EL levels with HDL cholesterol content and size does 
not exclude the catabolic role of the enzyme. In the MetS group, where plasma levels of neither EL nor LHDL-p 
were significantly modulated by venous volume overload, EL was significantly negatively correlated with LHDL-p 
(Table 3). This is in line with increased HDL particle plasma concentrations in patients with partial and complete 
loss-of-function mutations in the EL gene as well as in EL genetic variants exhibiting decreased EL activity15, 16. 
Although the positive correlation between EL and SHDL-p was not significant a significant negative correlation 
between EL plasma levels and HDL-s in the MetS group (Table 3) corroborates the established role of EL in the 
generation of SHDL-p16.
It is important to note that besides EL, LPL and hepatic lipase (HL) shape the serum lipoprotein profile in 
healthy subjects and MetS patients9. Considering the decreased LPL activity in MetS together with its role in 
the HDL biogenesis26, 27 it is possible that the negative correlation of EL and LHDL-p is, at least in part, a conse-
quence of the decreased LPL activity in MetS patients. Similarly, the strong positive correlation between EL and 
triglycerides in the MetS group is most likely the reflection of the concomitant increase in EL and triglycerides, 
the latter due to decreased LPL activity28, a consequence of low-grade inflammation in MetS. A previous study 
revealed no association between EL levels and HDL subclasses in healthy subjects29. The discrepancy between 
those results and ours might partly be due to different methodologies used for the evaluation of HDL subclasses 
namely NMR-spectroscopy used in our study, and the lipoprotein precipitation method30 used in theirs29.
Previous studies showed altered SN1 lipase activities in obesity and a pronounced influence of the degree of 
insulin resistance on EL activity9. Furthermore, the association of EL plasma levels with HDL-cholesterol- and 
HDL-phospholipid- levels, that is present in non-obese subjects, was not observed in subjects with excess adi-
pose tissue levels17. Considering the influence of adiposity on lipoprotein size and subclass concentrations31, as 
well as on EL plasma levels17 together with increased EL phospholipase activity in obese and insulin resistant 
subjects9, we assumed that a higher BMI and the pronounced positive correlation between EL and BMI in the 
no-MetS MetS
No 
Sign(s) 
n = 18
Sign(s) 
n = 49 p-value
No 
Sign(s) 
n = 24
Sign(s) 
n = 61 p-value
EL (pg/mL)
504.6 
[246.0–
1013.4]
362.0 
[74.1–
913.3]
0.030
566.1 
[256.7–
1407.7]
459.1 
[157.6–
1387.6]
0.157
Total cholesterol (mmol/L) 5.7 [2.5–9.1]
3.7 
[2.2–8.5] 0.001
4.2 
[2.5–6.4]
3.8 
[1.7–7.7] 0.134
LDL-cholesterol (mmol/L) 3.7 [1.4–6.3]
2.2 
[0.8–6.1] 0.008
2.4 
[1.3–4.5]
2.1 
[1.0–6.0] 0.117
HDL-cholesterol (mmol/L) 1.4 [0.6–2.3]
1.0 
[0.5–1.9] 0.002
1.0 
[0.4–1.4]
0.9 
[0.3–3.6] 0.490
Triglycerides (mmol/L) 1.1 [0.6–2.8]
0.9 
[0.5–3.0] 0.015
1.5 
[0.6–4.3]
1.1 
[0.6–3.2] 0.041
LVLDL-p (nmol/L) 2.5 [1.5–5.1]
1.7 
[1.5–3.7] 0.077
3.0 
[1.7–8.3]
2.7 
[1.5–10.6] 0.239
TLDL-p (nmol/L)
1530 
[564–
2488]
1084.5 
[615–
2437]
0.110
1352.5 
[614–
2425]
1081.0 
[360–
2351]
0.091
LLDL-p (nmol/L)
980.5 
[312–
2078]
625.0 
[304–
1870]
0.022
740.0 
[320–
1154]
654.0 
[300–
1160]
0.211
SLDL-p (nmol/L)
410.0 
[176–
1082]
471.0 
[236–
1440]
0.073
567.5 
[349–
1331]
451.0 
[172–
1191]
0.030
THDL-p (nmol/L)
30463 
[8741–
37506]
19140 
[3711–
30373]
<0.001
26083 
[9668–
36951]
20050 
[7910–
36377]
0.006
LHDL-p (nmol/L)
6212 
[4748–
14204]
6317.5 
[2943–
14726]
0.690
4481.5 
[2829–
7123]
4761 
[2835–
14921]
0.231
SHDL-p (nmol/L)
24486.5 
[15680–
32390]
14918.5 
[7086–
23044]
<0.001
21729 
[13532–
34210]
15246 
[6332–
28611]
0.001
Table 4. EL and lipid/lipoprotein plasma levels in patients without or with sign(s) implying volume overload. 
Results are presented as median, minimum and maximum. Significant differences between patients with no 
sign(s) and those with one or combination of two or three sign(s) implying volume overload were calculated 
with Mann-Whitney U-test and are depicted in bold. HDL-high density lipoprotein; LDL-low-density 
lipoprotein; EL-endothelial lipase; LVLDL-p –large very low-density lipoprotein particles; TLDL-p –total LDL 
particles; LLDL-p –large LDL particles; SLDL-p –small LDL-p; THDL-p –total HDL-particles; LHDL-p –large 
HDL-p; SHDL-p –small HDL-p; VLDL-s –VLDL size; LDL-s –LDL size; HDL-s –HDL size.
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MetS group (unadjusted: rho = 0.29, p = 0.008; adjusted for T2DM: rho = 0.27, p = 0.016) might, at least in part, 
explain the different associations between EL- and lipid/lipoprotein- plasma levels in the MetS and no-MetS 
groups. However, partial correlation analyses showed only a weak impact of BMI (Supplementary Table S5), waist 
circumference (Supplementary Table S6) and T2DM (Supplementary Table S1) on the correlation between EL- 
and lipid/lipoprotein plasma levels in both the no-MetS and the MetS group.
Increased EL levels and altered lipid/lipoprotein levels in MetS might be responsible for a less pronounced 
impact of venous volume overload on EL- and lipid/lipoprotein- levels in the MetS patients than in the no-MetS 
patients. The significant positive association of EL- and SLDL-p- levels and the significant negative association 
of EL and LDL-s in the MetS group is in accordance with the promotion of the catabolism of apoB-lipoprotein- 
containing lipoproteins observed in a hyperlipidaemic mouse model32. The results of our study regarding EL can 
be compared with a previous study, which revealed a positive association of HL and small, dense LDL-p33.
While we found no correlation between EL and IL-6 plasma levels (not shown), a significant positive correla-
tion was established between EL and CRP, but only in the MetS group (rho: 0.24; p = 0.032). The absence of cor-
relation in the no-MetS group could be due to the pathophysiology of the underlying volume overload, causing 
a pronounced significant increase in CRP (Supplementary Fig. S1) with concomitantly decreased EL (Table 4).
This study has several limitations: The insufficient quality of NMR-spectra obtained for some lipoprotein 
subfractions resulted in differing numbers of patients in which particular lipoprotein subfractions could be ana-
lysed. Although previous studies showed that pre- and post-heparin EL plasma levels are highly correlated8 or 
similar34, the possibility cannot be excluded that post-heparin EL plasma levels would be differently affected by 
AHF-associated pathophysiological conditions and MetS compared to our findings with pre-heparin EL plasma 
levels. Furthermore, considering EL polymorphisms associated with decreased EL enzyme activity15, 16, together 
with possibly altered plasma levels of EL inhibitors, such as angiopoetin-like protein 335 or protein convertases36 
in AHF, the association of EL activity with plasma lipids/lipoproteins9 might be different from what was found 
for the EL mass in this study. The study examined only the relationship between EL and HDL levels without 
addressing HDL functionality, a factor that is more important than HDL levels37, and can be studied by a variety 
of available experimental methods38. Based on our results, we conclude that the association of EL and atherogenic 
lipid profile is altered in AHF and additionally modified by MetS, which also strongly modulates EL- and lipid/
lipoprotein- plasma levels in AHF.
Methods
Study design and patients. The AHF study was performed as an observational single-centre study and 
included consecutive white adult hospitalised AHF patients. The study was approved by the Ethics Committee 
of the University Hospital Centre Sisters of Charity, Zagreb, and of the Medical University of Graz. The inves-
tigation conforms with the principles outlined in the Declaration of Helsinki principles39, and informed consent 
was obtained in compliance with Good Clinical Practice. 152 patients were recruited from November 2013 to 
February 2015 as described40. Categorisation of the patients was performed according to the European Society 
of Cardiology (ESC) and ACCF/AHA Guidelines for HF41–43 and patients were treated by the standard ESC 
Guidelines for AHF42, 43. MetS was defined as the manifestation of three or more of the following five abnormal-
ities: central obesity, hypertriglyceridaemia, lowered HDL-cholesterol, glucose intolerance or elevated fasting 
glucose and hypertension44. Hypertension was diagnosed according to the ESC criteria45. Diabetes was diagnosed 
in patients with dietary treatment, antidiabetic medication or current fasting plasma glucose levels higher than 
7.0 mmol/L46. Hypercholesterolaemia was defined as LDL-cholesterol levels higher than 3.5 mmol/L, or taking a 
lipid-lowering drug and hypertriglyceridaemia was defined as triglyceride levels higher than 1.7 mmol/L. Patients 
were also classified according to three signs implying volume overload (enlarged liver, peripheral oedema or 
ascites) as a consequence of right-sided HF into those having none of the signs (no sign(s)) and those having at 
least one sign (sign(s)). Patients with severe renal failure (serum creatinine ≥400 mmol/L), renal replacement 
therapy, hepatic cirrhosis, malignancy, trauma, surgical diseases, pregnancy, major systemic disease or younger 
than 18 years were not included in the study.
Laboratory assays. For routine laboratory assays blood was obtained at admission to the hospital. It 
was collected in 6 mL tubes, VACUETTE® Z Serum Clot Activator (Greiner Bio-one GmbH, Kremsmuenster, 
Austria). The serum aliquots were stored at −80 °C. The Beckman Coulter instrument AU 2700, 2007 (Brea, 
CA, USA) and Architect c8000, Abbott 2013 (Chicago, IL, USA) were used to measure total plasma choles-
terol, LDL-cholesterol, HDL-cholesterol, triglycerides and CRP. A specific chemiluminescent ELISA (QuantiGlo; 
R&D Systems, Wiesbaden-Nordenstadt, Germany) was used to measure IL-6 concentrations and with Human 
Endothelial Lipase Assay Kit (TaKaRa, Takara Bio Europe S.A.S., Saint-Germain-en-Laye, France) were measured 
pre-heparin EL protein levels, according to the manufacturer’s instructions.
Lipoprotein profiling by Nuclear Magnetic Resonance (NMR) spectroscopy. The lipoprotein 
profiles of 138 serum samples were analysed with the AXINON® lipoFIT®-S100 test system (Numares Health, 
Regensburg, Germany). NMR spectra were recorded at a temperature of 310 K on a shielded 600 MHz Bruker 
Avance III HD spectrometer as described47. To ensure data quality only spectra meeting defined quality criteria 
were used for analyses. The number (n) of analysed samples is indicated in Table 2.
Statistical analysis. Categorical data are shown as absolute and relative frequencies, and continuous data 
are presented as mean and SD or as median and range (minimum to maximum) depending on distribution. The 
differences between patients with and without metabolic syndrome were assessed by t-test or Mann-Whitney 
U test for continuous parameters and by Fisher’s exact test for categorical parameters. In addition, the differ-
ences between patients with and without sign(s) implying volume overload were assessed within the groups 
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using Mann-Whitney U test. The Spearman correlation coefficients were calculated to evaluate the correlation 
of EL plasma levels and laboratory parameters. In addition, the differences between patients with and without 
sign(s) implying venous volume overload (enlarged liver, peripheral oedema or ascites), were assessed within the 
metabolic syndrome groups using Mann-Whitney U test. Furthermore, the impact of T2DM, sign(s) implying 
venous volume overload, BMI, waist circumference and NYHA classes (2/3 vs. 4) on the correlations between EL 
and lipid parameters was assessed by means of partial correlations. A p-value < 0.05 was considered statistically 
significant and results are to be interpreted in an exploratory fashion. All data were analysed using R version 3.3.1.
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